A Phase 1/2 Trial of TER-2013
Phase 1/2
205
about 3.4 years
18+
14 sites in FL, MA, MN +9
About this study
This trial is testing a treatment called TER-2013 in people with advanced solid tumors that have changes in the AKT/PI3K/PTEN pathway. The goal is to see if it's safe, well-tolerated, and effective at fighting cancer.
Based on ClinicalTrials.gov records.
What participants do
- 1.Receive Fulvestrant injection
- 2.Take TER-2013
Participation effort
Estimated from trial records. Details can vary by site.
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
fulvestrant
injection
Primary: Duration of Response as assessed by RECIST v1.1, Number of Patients who Experience Dose-Limiting Toxicity, Number of patients who experience a treatment-related adverse event, Objective Response Rate as assessed by RECIST v1.1
Secondary: Area under the plasma concentration-time curve for a dosing interval (AUCτ) of TER-2013, Changes of pharmacodynamic markers of TER-2013 in tissue and/or blood as assessed by pAKT, Changes of pharmacodynamic markers of TER-2013 in tissue and/or blood as assessed by pPRAS40, Maximum concentration (Cmax) of TER-2013, Terminal elimination half-life (T1/2) of TER-2013, Time to maximum concentration (Tmax) of TER-2013
Oncology